Marketing Authorisation Withdrawn
On 13 December 2019, Tesaro ceased the commercialization of rolapitant (as hydrochloride monohydrate) 90mg film-coated tablets (Varuby).
Medicine details
- Medicine name:
- rolapitant (Varuby)
- SMC ID:
- 1266/17
- Indication:
Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy.
- Pharmaceutical company
- Tesaro UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 11 September 2017
On 13 December 2019, Tesaro ceased the commercialization of rolapitant (as hydrochloride monohydrate) 90mg film-coated tablets (Varuby).The decision to cease commercialization is not due to efficacy, safety or public health issues.
Tesaro will not accept further orders of Varuby 90mg (rolapitant). For treatment continuity, if stock is available, healthcare professionals may continue to prescribe and pharmacists can continue to dispense.